Neurological Biomarkers Market, by Biomarker Type (Imaging Biomarkers, Metabolomics Biomarkers, Proteomic Biomarkers, and Genomics Biomarkers), by Application (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, and Ot

Neurological Biomarkers Market, by Biomarker Type (Imaging Biomarkers, Metabolomics Biomarkers, Proteomic Biomarkers, and Genomics Biomarkers), by Application (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, and Others), by End User (Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Neurological biomarkers are biological indicators present in the cerebrospinal fluid that can be measured to study the health of the brain. Neurological biomarkers can be of various types such as imaging biomarkers, metabolomics biomarkers, proteomic biomarkers, and genomics biomarkers. Neurological biomarkers help in the early diagnosis of neurological disorders such as epilepsy, brain tumor, Alzheimer’s, Parkinson’s disease, multiple sclerosis, and others. These biomarkers also assist in monitoring the progress of a neurological disease and studying biological response towards a treatment. Neurological biomarkers captures different characteristics of a disease such as pathogenicity and heterogeneity, which helps in the development of personalized treatment therapy. Rapid research and technological advances in the field of neurology has led to introduction of novel biomarkers that are accurate, reliable and sensitive. According to an article published by the Frontiers in Neurology Journal in January 2019, a computational analysis of gene expression data was carried out in Alzheimer’s disease patients to predict blood-based biomarkers, where the experimental validation was conducted using Enzyme Linked Immuno-sorbent Assay (ELISA) and Western blot analyses. This study led to the discovery of novel neurological biomarker- VLDLR (Very Low Density Lipoprotein Receptor) as a biomarker for Alzheimer's disease.

Market Dynamics

Market players and research organizations are conducting clinical trial studies for finding out novel neurological biomarkers, which could contribute to the growth of the market over the forecast period. For instance, a clinical study based on neurological biomarkers was initiated by IRCCS Neuromed Mediterranean Neurological Institute, Italy in March 2019, which is expected to be completed by January 2023. This study investigates the use of circulating, cell-free mitochondrial DNA (ccf-mtDNA) as a neurological biomarker for the early detection and prognosis of multiple sclerosis. Such clinical studies is expected to create opportunities for neurological biomarkers market over the forecast period.

Market players are focusing on the launch of products, which is expected to strengthen their position in the global neurological biomarkers market. For instance, in 2018, Biosensis, an Australian manufacturer of life science reagents, launched new BDNF ELISA Kit for accurate measurement of two important blood biomarkers BDNF and pro-BDNF in under four hours. Brain-derived neurotrophic factor (BDNF) biomarker is an important indicator for various neurological and psychiatric disorders such as clinical depression.

Market players are involved in expanding their presence globally, by entering into partnership with other companies in order to enhance distribution, this is expected to drive the growth of the neurological biomarkers market. For instance, in January 2017, Banyan Biomarkers, an American diagnostic tool company, entered into partnership with BioMerieux, a French biotechnology company, to validate and commercialize blood-based neurological biomarkers for in vitro diagnostics for traumatic brain injury (TBI).

Key features of the study:
This report provides an in-depth analysis of global neurological biomarkers market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global neurological biomarkers market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Abbott Laboratories, QIAGEN N.V., Myriad RBM, Thermo Fisher Scientific Inc., Athena Diagnostics, Bio-Rad Laboratories, Inc., AbaStar MDx, Inc., Acumen Pharmaceuticals, Banyan Biomarkers, Inc., Alseres Pharmaceuticals, Inc., Proteome Sciences, Immunarray Pvt. Ltd., Quanterix Corporation, Diagenic ASA, and Psynova Neurotech
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global neurological biomarkers market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global neurological biomarkers market
Detailed Segmentation:
Global Neurological Biomarkers Market, By Biomarker Type:
Imaging biomarkers
Metabolomics Biomarkers
Proteomic Biomarkers
Genomics Biomarkers
Global Neurological Biomarkers Market, By Application:
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Autism Spectrum Disorders
Others
Global Neurological Biomarkers Market, By End User:
Hospital Laboratories
Clinical Diagnostic Centers
Research Organizations
Others
Global Neurological Biomarkers Market, By Region:
North America
By Biomarker Type:
Imaging biomarkers
Metabolomics Biomarkers
Proteomic Biomarkers
Genomics Biomarkers
By Application:
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Autism Spectrum Disorders
Others
By End User:
Hospital Laboratories
Clinical Diagnostic Centers
Research Organizations
Others
By Country:
U.S.
Canada
Latin America
By Biomarker Type:
Imaging biomarkers
Metabolomics Biomarkers
Proteomic Biomarkers
Genomics Biomarkers
By Application:
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Autism Spectrum Disorders
Others
By End User:
Hospital Laboratories
Clinical Diagnostic Centers
Research Organizations
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Biomarker Type:
Imaging biomarkers
Metabolomics Biomarkers
Proteomic Biomarkers
Genomics Biomarkers
By Application:
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Autism Spectrum Disorders
Others
By End User:
Hospital Laboratories
Clinical Diagnostic Centers
Research Organizations
Others
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Biomarker Type:
Imaging biomarkers
Metabolomics Biomarkers
Proteomic Biomarkers
Genomics Biomarkers
By Application:
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Autism Spectrum Disorders
Others
By End User:
Hospital Laboratories
Clinical Diagnostic Centers
Research Organizations
Others
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Biomarker Type:
Imaging biomarkers
Metabolomics Biomarkers
Proteomic Biomarkers
Genomics Biomarkers
By Application:
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Autism Spectrum Disorders
Others
By End User:
Hospital Laboratories
Clinical Diagnostic Centers
Research Organizations
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Biomarker Type:
Imaging biomarkers
Metabolomics Biomarkers
Proteomic Biomarkers
Genomics Biomarkers
By Application:
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Autism Spectrum Disorders
Others
By End User:
Hospital Laboratories
Clinical Diagnostic Centers
Research Organizations
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Abbott Laboratories*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
QIAGEN N.V.
Myriad RBM
Thermo Fisher Scientific Inc.
Athena Diagnostics
Bio-Rad Laboratories, Inc.
AbaStar MDx, Inc.
Acumen Pharmaceuticals
Banyan Biomarkers, Inc.
Alseres Pharmaceuticals, Inc.
Proteome Sciences
Immunarray Pvt. Ltd.
Quanterix Corporation
Diagenic ASA
Psynova Neurotech
“*” marked represents similar segmentation in other categories in the respective section.